E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment of Respiratory Distress Syndrome (RDS) in spontaneously breathing preterm neonates. |
|
E.1.1.1 | Medical condition in easily understood language |
Treatment of Respiratory Distress Syndrome (RDS) in spontaneously breathing preterm neonates. |
|
E.1.1.2 | Therapeutic area | Not possible to specify |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of this study is to evaluate the safety profile of the administration of porcine surfactant (poractant alfa, Curosurf®) through a less invasive method (LISA) using a thin catheter (CHF 6440) during non-invasive ventilation (NIV), compared to conventional surfactant administration during invasive ventilation and rapid extubation, in spontaneously breathing preterm neonates with clinical signs of respiratory distress syndrome (RDS). The short-term and mid-term safety will be assessed: adverse events and adverse drug reactions occurring during overall procedure for surfactant administration, neonatal pain assessment pre- and during surfactant administration, duration of surfactant administration, incidence of bronchopulmonary dysplasia (BPD) at 36 weeks post menstrual age (PMA) , major neonatal morbidities and vital signs. |
|
E.2.2 | Secondary objectives of the trial |
Short-term and mid-term efficacy profile will also be assessed mainly in terms of: reduced oxygen requirement and ventilatory support, need for invasive mechanical ventilation in the first 72 hours of life and throughout the study period, duration of invasive and non-invasive ventilation and need for additional surfactant doses. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects must meet all the following inclusion criteria to be eligible for enrollment into the study: 1. Written informed consent obtained by parents/legal representative (according to local regulation) prior to or after birth; 2. Preterm neonates of either sex aged ≥30 minutes and <24 hours, spontaneously breathing and stabilized on NIV; 3. Gestational age of 25+0 weeks up to 28+6 completed weeks; enrollment will be restricted to subjects aged 27+0 weeks up to 28+6 GA weeks until safety evaluation of first 15 subjects is completed; 4. Clinical course consistent with RDS; 5. FiO2 ≥0.30 to maintain preductal SpO2 in the target range of 88–95%. |
|
E.4 | Principal exclusion criteria |
The presence of any of the following will exclude a subject from the study enrollment: 1. Need for immediate endotracheal intubation for cardiopulmonary resuscitation or insufficient respiratory drive; 2. Use of nasal high frequency oscillatory ventilation (nHFOV) prior to study entry; 3. Use of surfactant prior to study entry and need for intratracheal administration of any other treatment (e.g. nitric oxide); 4. Known genetic or chromosomal disorders, major congenital anomalies (congenital heart diseases, myelomeningocele, etc); 5. Mothers with prolonged premature rupture of the membranes (>21 days duration) which could cause complications (in particular severe pulmonary hypoplasia due to oligohydramnios); 6. Presence of air leaks if identified and known prior to study entry; 7. Evidence of severe birth asphyxia (e.g. continued need for resuscitation at 10 minutes after birth, altered neurological state or neonatal encephalopathy); 8. Neonatal seizures prior to study entry; 9. Any condition that, in the opinion of the Investigator, would place the neonate at undue risk; 10. Participation in another clinical trial of any medicinal product, placebo, experimental medical device or biological substance conducted under the provisions of a protocol on the same therapeutic target; the participation in studies involving diagnostic devices or studies with treatments for different conditions than lung and respiratory function impairments may be permitted following an agreement with the sponsor. Non-interventional observational studies are allowed. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Main Safety Outcome: Number and percentage of neonates with adverse events started during the procedure for surfactant administration and judged related to the procedure; 2. Main Safety Outcome: Incidence of AEs (including neonatal complications of prematurity), incidence of adverse drugs reactions, incidence of serious adverse events, incidence of AEs leading to death; 3. Main Safety Outcome: Number of first failed attempts to insert the catheter/endotracheal tube and percentage of neonates with first failed attempt; 4. Main Safety Outcome: Incidence of death at 36 weeks PMA; 5. Main Safety Outcome: Incidence of bronchopulmonary dysplasia at 36 weeks PMA; 6. Main Safety Outcome: Health status at discharge or 40 weeks PMA (whichever comes first): feeding status, hearing status, growth parameters, need for respiratory support or respiratory medication. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. [Time Frame: From the application of the laryngoscope up to the removal of the CHF 6440 catheter or the endotracheal tube] 2. [Time Frame: From the application of the laryngoscope up to the end of the main phase of the study (discharge or 40 weeks Post-Menstrual Age [PMA], whichever comes first)] 3. [Time Frame: At first surfactant administration] 4. [Time Frame: 36 weeks PMA] 5. [Time Frame: 36 weeks PMA] 6.[Time Frame: Discharge or 40 weeks PMA (whichever comes first)].
|
|
E.5.2 | Secondary end point(s) |
1. Main Efficacy Outcome: Percentage of neonates needing invasive mechanical ventilation; 2. Main Efficacy Outcome: Median duration of invasive mechanical ventilation; 3. Main Efficacy Outcome: Preductal Oxygen Saturation (SpO2), Fraction of Inspired Oxygen (FiO2) and SpO2/FiO2 ratio; 4. Main Efficacy Outcome: Percentage of neonates requiring at least one additional surfactant dose. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Main Efficacy Outcome: Percentage of neonates needing invasive mechanical ventilation [Time Frame: First 72 hours of life, Up to 28 days Post-Natal Age (PNA), Up to 36 weeks PMA] 2. Main Efficacy Outcome: Median duration of invasive mechanical ventilation [Time Frame: First 72 hours of life, Up to 28 days PNA, Up to 36 weeks PMA] 3. Main Efficacy Outcome: Preductal Oxygen Saturation (SpO2), Fraction of Inspired Oxygen (FiO2) and SpO2/FiO2 ratio [Time Frame: Time 0 (study treatment administration), 5, 15, 30 minutes, at 1, 6, 12, 24, 48, 72 and 120 hours post treatment] 4. Main Efficacy Outcome: Percentage of neonates requiring at least one additional surfactant dose [Time Frame: First 72 hours of life] |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Conventional administration of Curosurf during brief invasive ventilation. |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 0 |